| Identification | Back Directory | [Name]
TUG 891 | [CAS]
1374516-07-0 | [Synonyms]
TUG 891
CS-2448
TUG 891;TUG-891
4-[(4-Fluoro-4'-methyl[1,1'-biphenyl]-2-yl)methoxy]-benzenepropanoic acid
Benzenepropanoic acid, 4-[(4-fluoro-4'-methyl[1,1'-biphenyl]-2-yl)methoxy]- | [Molecular Formula]
C23H21FO3 | [MDL Number]
MFCD22421654 | [MOL File]
1374516-07-0.mol | [Molecular Weight]
364.41 |
| Chemical Properties | Back Directory | [Boiling point ]
540.8±50.0 °C(Predicted) | [density ]
1.199±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMSO:30.0(Max Conc. mg/mL);82.32(Max Conc. mM)
DMF:5.0(Max Conc. mg/mL);13.72(Max Conc. mM)
Ethanol:1.0(Max Conc. mg/mL);2.74(Max Conc. mM) | [form ]
Powder | [pka]
4.70±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
TUG 891 is a potent and selective GPR120 agonist as a new potential target for treatment of type 2 diabetes and metabolic diseases. | [Biological Activity]
TUG-891 is an orally activepotent and selective agonist for human long chain free fatty acid (FFA) receptor FFA4/GPR120 (pEC50 of receptor β-arrestin-2 recruitment = 7.36/FFA4 vs. 4.19/FFA1 HEK transfectants; pEC50 of calcium mobilization = 7.02/FFA4 vs. 5.30/FFA1 transfectants)while exhibiting no activity toward human short-chain FFA receptors FFA2/GPR43 and FFA3/GPR41. TUG-891 also exhibits potent partial agonist activity toward murine FFA4 (pEC50 = 7.7775% efficacy by β-arrestin-2 recruitment assay; pEC50 = 6.89 by calcium mobilization)albeit with a reduced selectivity over mFFA1 (pEC50 = 5.92 by β-arrestin-2 recruitment and 6.41 by by calcium mobilization). When administered via water intake (~20 mg/kg/day)TUG-891 is reported to reverse food intake increases and body weight gains among mice subjected to sleep fragmentationand significantly attenuate visceral white adipose tissue inflammation as well as insulin resistance.''TUG-891a GPR120 agonist he | [storage]
Store at RT |
|
|